Active Ingredient History
Rivaroxaban (trade name Xarelto) is an oral anticoagulant. It is the first available orally active direct factor Xa inhibitor. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels. Activation of factor X to factor Xa (FXa) via the intrinsic and extrinsic pathways plays a central role in the cascade of blood coagulation. Xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prophylaxis of deep vein thrombosis (DVT) which may lead to PE in patients undergoing knee or hip replacement surgery, pulmonary embolism (PE) and for the reduction in the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial 6 months treatment for DVT and/or PE. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Pulmonary Embolism (approved 2011)
Acute Coronary Syndrome (Phase 4)
Anemia, Sickle Cell (Phase 3)
Aneurysm (Phase 3)
Angina, Stable (Phase 4)
Angina, Unstable (Phase 4)
Anticoagulants (Phase 4)
Antiphospholipid Syndrome (Phase 4)
Aortic Valve Disease (Phase 2)
Aortic Valve Insufficiency (Phase 4)
Aortic Valve Stenosis (Phase 4)
Appendix (Phase 4)
Arthritis (Phase 3)
Arthroplasty (Phase 4)
Atherosclerosis (Phase 4)
Atrial Appendage (Phase 2/Phase 3)
Atrial Fibrillation (Phase 4)
Atrial Flutter (Phase 4)
Bariatric Surgery (Phase 2)
beta-Thalassemia (Phase 2)
Biological Availability (Phase 1)
Blood Coagulation (Phase 1)
Blood Loss, Surgical (Phase 4)
Brain Ischemia (Phase 2/Phase 3)
Breast Neoplasms (Phase 1)
Carcinoma, Hepatocellular (Phase 2)
Cardiomyopathies (Phase 4)
Cardiovascular Diseases (Phase 4)
Carotid Stenosis (Phase 4)
Cerebral Hemorrhage (Phase 3)
Cerebral Infarction (Phase 4)
Cerebral Intraventricular Hemorrhage (Phase 3)
Cerebrovascular Disorders (Phase 3)
Chronic Limb-Threatening Ischemia (Phase 2)
Colonic Neoplasms (Phase 4)
Communicable Diseases (Phase 3)
Constriction, Pathologic (Phase 2/Phase 3)
Coronary Aneurysm (Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Coronavirus Infections (Phase 4)
COVID-19 (Phase 4)
Diabetes Mellitus (Phase 4)
Drug Interactions (Phase 1)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 1)
Duodenal Neoplasms (Phase 2)
Electric Countershock (Phase 3)
Embolism (Phase 4)
Embolism and Thrombosis (Phase 4)
Esophageal Neoplasms (Phase 2)
Femoral Neck Fractures (Phase 4)
Femur Head Necrosis (Phase 4)
Fibrinolytic Agents (Phase 3)
Fibrosis (Phase 3)
Foramen Ovale, Patent (Phase 4)
Gastric Bypass (Phase 1)
General Surgery (Phase 3)
Healthy Volunteers (Phase 2/Phase 3)
Heart Failure (Phase 4)
Heart Valve Diseases (Phase 3)
Heart Valve Prosthesis Implantation (Phase 2)
Hematoma (Phase 3)
Hematoma, Subdural (Phase 3)
Hemodialysis, Home (Phase 3)
Hemorrhage (Phase 4)
Hip Fractures (Phase 3)
Hypertension, Portal (Phase 1/Phase 2)
Hypertrophy, Left Ventricular (Phase 4)
Immune System Diseases (Phase 1)
Immunotherapy (Phase 1)
Inflammation (Phase 1)
Intermittent Claudication (Phase 4)
Intestinal Neoplasms (Phase 2)
Intracranial Arteriosclerosis (Phase 2/Phase 3)
Intracranial Hemorrhage, Hypertensive (Phase 3)
Intracranial Hemorrhages (Phase 3)
Ischemic Attack, Transient (Phase 4)
Ischemic Stroke (Phase 4)
Kidney Failure, Chronic (Phase 4)
Liver Cirrhosis (Phase 1/Phase 2)
Lung Diseases (Phase 4)
Lung Neoplasms (Phase 1)
Lupus Erythematosus, Systemic (Phase 2/Phase 3)
May-Thurner Syndrome (Phase 3)
Menstruation (Phase 2/Phase 3)
Migraine Disorders (Phase 4)
Mitral Valve Stenosis (Phase 4)
Mucocutaneous Lymph Node Syndrome (Phase 3)
Multiple Myeloma (Phase 2/Phase 3)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 4)
Neoplasms (Phase 4)
Non-ST Elevated Myocardial Infarction (Phase 4)
Obesity, Morbid (Phase 1)
Osteoarthritis, Hip (Phase 4)
Osteoarthritis, Knee (Phase 4)
Pancreatic Neoplasms (Phase 2)
Pediatrics (Phase 1)
Percutaneous Coronary Intervention (Phase 3)
Peripheral Arterial Disease (Phase 4)
Pharmacokinetics (Phase 1)
Pharmacology, Clinical (Phase 1)
Postthrombotic Syndrome (Phase 4)
Prostatic Neoplasms (Phase 1)
Prostheses and Implants (Phase 2/Phase 3)
Pulmonary Embolism (Phase 4)
Radial Artery (Phase 3)
Recurrence (Phase 4)
Renal Insufficiency (Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Respiratory Insufficiency (Phase 3)
Respiratory Tract Diseases (Phase 4)
Rheumatic Diseases (Phase 3)
Rheumatic Heart Disease (Phase 3)
Rivaroxaban (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Stomach Neoplasms (Phase 2)
Stroke (Phase 4)
Subarachnoid Hemorrhage (Phase 3)
Therapeutic Equivalency (Phase 1)
Thrombocytopenia (Phase 3)
Thromboembolism (Phase 4)
Thrombosis (Phase 4)
Transcatheter Aortic Valve Replacement (Phase 3)
Upper Extremity Deep Vein Thrombosis (Phase 4)
Urinary Bladder Neoplasms (Phase 2)
Urologic Neoplasms (Phase 2/Phase 3)
Vascular Calcification (Phase 4)
Vascular Grafting (Phase 3)
Venous Thromboembolism (Phase 4)
Venous Thrombosis (Phase 4)
Ventricular Outflow Obstruction (Phase 3)
Warfarin (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
